The Indian Journal of Pediatrics

, Volume 82, Issue 6, pp 519–524 | Cite as

Growth Patterns of HIV Infected Indian Children in Response to ART: A Clinic Based Cohort Study

  • Ritu S. Parchure
  • Vinay V. Kulkarni
  • Trupti S. Darak
  • Rahul Mhaskar
  • Branko Miladinovic
  • Patricia J. Emmanuel
Original Article

Abstract

Objective

To describe catch-up growth after antiretroviral therapy (ART) initiation among children living with human immunodeficiency virus (CLHIV), attending a private clinic in India.

Methods

This is a retrospective analysis of data of CLHIV attending Prayas clinic, Pune, India. Height and weight z scores (HAZ, WAZ) were calculated using WHO growth charts. Catch-up growth post-ART was assessed using a mixed method model in cases where baseline and at least one subsequent follow-up HAZ/WAZ were available. STATA 12 was used for statistical analysis.

Results

During 1998 to 2011, 466 children were enrolled (201 girls and 265 boys; median age = 7 y). A total of 302 children were ever started on ART; of which 73 and 76 children were included for analysis for catch up growth in WAZ and HAZ respectively. Median WAZ and HAZ increased from −2.14 to −1.34 (p = 0.007) and −2.42 to −1.94 (p = 0.34), respectively, 3 y post ART. Multivariable analysis using mixed model (adjusted for gender, guardianship, baseline age, baseline WAZ/HAZ, baseline and time varying WHO clinical stage) showed gains in WAZ (coef = 0.2, 95 % CI: −0.06 to 0.46) and HAZ (coef = 0.49, 95 % CI: 0.21 to 0.77) with time on ART. Lower baseline WAZ/HAZ and older age were associated with impaired catch-up growth. Children staying in institutions and with baseline advanced clinical stage showed higher gain in WAZ.

Conclusions

The prevalence of stunting and underweight was high at ART initiation. Sustained catch-up growth was seen with ART. The study highlights the benefit of early ART in achieving normal growth in CLHIV.

Keywords

HIV/AIDS HIV infected children Anti-retroviral therapy Catch up growth Growth failure 

References

  1. 1.
    Newell ML, Borja MC, Peckham C; European Collaborative Study. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics. 2003;111:e52–60.Google Scholar
  2. 2.
    Lepage P, Msellati P, Hitimana DG, Bazubagira A, van Goethem C, Simonon A, et al. Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda, 1988 to 1993. Pediatr Infect Dis J. 1996;15:479–85.CrossRefPubMedGoogle Scholar
  3. 3.
    Ram M, Gupte N, Nayak U, Kinikar AA, Khandave M, Shankar AV, et al; SWEN India and BJMC-JHU Clinical Trials Study Team. Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India. BMC Infect Dis. 2012;12:282.Google Scholar
  4. 4.
    Collins IJ, Jourdain G, Hansudewechakul R, Kanjanavanit S, Hongsiriwon S, Ngampiyasakul C, et al; Program for HIV Prevention and Treatment Study Team. Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis. 2010;51:1449–57.Google Scholar
  5. 5.
    Weigel R, Phiri S, Chiputula F, Gumulira J, Brinkhof M, Gsponer T, et al. Growth response to antiretroviral treatment in HIV-infected children: a cohort study from Lilongwe, Malawi. Trop Med Int Health. 2010;15:934–44.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics. 2002;109:E25.CrossRefPubMedGoogle Scholar
  7. 7.
    Nachman SA, Lindsey JC, Moye J, Stanley KE, Johnson GM, Krogstad PA, et al. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2005;24:352–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Guillen S, Ramos JT, Resino R, Bellon JM, Munoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J. 2007;26:334–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Kekitiinwa A, Lee KJ, Walker AS, Maganda A, Doerholt K, Kitaka SB, et al. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr. 2008;49:384–92.CrossRefPubMedGoogle Scholar
  10. 10.
    Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS. 2008;22:245–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Aurpibul L, Puthanakit T, Taecharoenkul S, Sirisanthana T, Sirisanthana V. Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor–based antiretroviral therapy. AIDS Patient Care STDS. 2009;23:1067–71.CrossRefPubMedGoogle Scholar
  12. 12.
    Department of AIDS control (NACO). Annual Report 2012–13.Google Scholar
  13. 13.
    Panditrao M, Darak S, Kulkarni V, Kulkarni S, Parchure R. Socio-demographic factors associated with loss to follow-up of HIV infected women attending a private sector PMTCT program in Maharashtra, India. AIDS Care. 2011;23:593–600.CrossRefPubMedGoogle Scholar
  14. 14.
    Singh HK, Gupta A, Siberry GK, Gupte N, Sastry J, Kinikar A, et al. The Indian pediatric HIV epidemic: a systematic review. Curr HIV Res. 2008;6:419–32.CrossRefPubMedGoogle Scholar
  15. 15.
    Devi NP, Chandrasekaran K, Bhavani PK, Thiruvalluvan C, Swaminathan S. Persistence of stunting after highly active antiretroviral therapy in HIV-infected children in South India. Indian Pediatr. 2011;48:333–4.PubMedGoogle Scholar
  16. 16.
    Banerjee T, Pensi T, Banerjee D, Grover G. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India. Ann Trop Paediatr. 2010;30:27–37.CrossRefPubMedGoogle Scholar
  17. 17.
    Bandyopadhyay A, Bhattacharyya S. Effect of pre-existing malnutrition on growth parameters in HIV-infected children commencing antiretroviral therapy. Ann Trop Paediatr. 2008;28:279–85.CrossRefPubMedGoogle Scholar
  18. 18.
    WHO. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. 2006.Google Scholar
  19. 19.
    WHO. WHO Anthro (version 3.2.2, January 2011) and macros. 2012 [cited 2012 July 20]; Available from: http://www.who.int/childgrowth/software/en/.
  20. 20.
    WHO. Growth reference 5–19 years. 2012 [cited 2012 July 20]; Available from: http://www.who.int/growthref/tools/en/.
  21. 21.
    International Institute for Population Sciences (IIPS) and Macro International. National Family Health Survey (NFHS-3) 2005–06: India. Mumbai: IIPS; 2007.Google Scholar
  22. 22.
    Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888–99.CrossRefPubMedGoogle Scholar
  23. 23.
    Davies MA, Keiser O, Technau K, Eley B, Rabie H, van Cutsem G, et al; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Outcomes of the South African national antiretroviral treatment programme for children: the IeDEA Southern Africa collaboration. S Afr Med J. 2009;99:730–7.Google Scholar
  24. 24.
    Sutcliffe CG, van Dijk JH, Munsanje B, Hamangaba F, Sinywimaanzi P, Thuma PE, et al. Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: a cohort study. BMC Infect Dis. 2011;11:54.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Puthanakit T, Saphonn V, Ananworanich J, Kosalaraksa P, Hansudewechakul R, Vibol U, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis. 2012;12:933–41.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Anonymous. Natural history of vertically acquired human immunodeficiency virus-1 infection. The European Collaborative Study. Pediatrics. 1994;94:815–9.Google Scholar
  27. 27.
    Lumbiganon P, Kariminia A, Aurpibul L, Hansudewechakul R, Puthanakit T, Kurniati N, et al. Survival of HIV-infected children: a cohort study from the Asia-Pacific region. J Acquir Immune Defic Syndr. 2011;56:365–71.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Prendergast A, Bwakura-Dangarembizi MF, Cook AD, Bakeera-Kitaka S, Natukunda E, Nahirya Ntege P, et al. Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy. AIDS. 2011;25:951–6.CrossRefPubMedGoogle Scholar
  29. 29.
    World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO; 2013.Google Scholar
  30. 30.
    Puthanakit T, Bunupuradah T. Early versus deferred antiretroviral therapy in children in low-income and middle-income countries. Curr Opin HIV AIDS. 2010;5:12–7.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2015

Authors and Affiliations

  • Ritu S. Parchure
    • 1
  • Vinay V. Kulkarni
    • 1
  • Trupti S. Darak
    • 1
  • Rahul Mhaskar
    • 2
  • Branko Miladinovic
    • 2
  • Patricia J. Emmanuel
    • 3
  1. 1.PrayasPuneIndia
  2. 2.Center for Evidence Based Medicine and Health Outcomes ResearchUniversity of South FloridaTampaUSA
  3. 3.Department of Pediatrics, College of MedicineUniversity of South FloridaTampaUSA

Personalised recommendations